Selank and Semax: Should You Combine Them?

A first-time peptide user on r/peptides asked whether to add Semax to a planned course of Selank for generalized anxiety disorder (GAD), after being told the combination helps with focus. Start with the direct answer: nobody has published a study that gave both peptides to the same person, so there is no human interaction evidence either way. It also helps to separate the two premises behind the question. Selank has real, if small, human trial data specific to GAD. Semax's reputation for helping with focus does not rest on a comparable study in healthy people. Its human record is concentrated in stroke rehabilitation, not attention or concentration.

What Selank's own GAD evidence shows

Selank is a synthetic heptapeptide built from tuftsin, an immune-signaling peptide, and it is registered in Russia as an anxiolytic. The main human evidence for the GAD use case comes from Zozulia and colleagues, who in 2008 compared Selank in 30 people against the benzodiazepine medazepam in 32 people, all diagnosed with generalized anxiety disorder or neurasthenia^[1]. The trial reported comparable anxiolytic effects between the two arms, plus antiasthenic and psychostimulant effects specific to Selank. Mechanistically, a 2018 review describes Selank as a positive allosteric modulator at GABA receptors^[2], the same receptor family benzodiazepines act on, which is a plausible explanation for the trial's anxiolytic result. It is one 2008 trial of 62 people, not a large modern randomized program, and that scale should temper how much weight any single reader puts on it.

Semax's focus reputation is thinner than it sounds

The most-cited human evidence for Semax comes from ischemic stroke rehabilitation, not cognition in healthy people. Gusev and colleagues followed 110 stroke patients through a regimen the paper describes as two 10-day intranasal courses at 6,000 micrograms a day, and reported higher plasma brain-derived neurotrophic factor (BDNF) alongside better motor and Barthel-index recovery scores^[3]. That is a real result in a specific rehabilitation population. It says nothing about whether a healthy person trying to concentrate at a desk would notice anything. The closest thing to a focus mechanism in the published record is a rodent experiment: Eremin and colleagues found that Semax alone did not change striatal dopamine in mice, but that Semax given before D-amphetamine sharply amplified the amphetamine's dopamine release and locomotor effects^[4]. That is a stimulant-interaction signal in animals, not a human attention study, and it is not evidence that Semax by itself sharpens focus in a person who is not on amphetamine.

Stacking two untested-together peptides makes attribution harder

The one human study that put Selank and Semax inside a single protocol is a 2020 resting-state fMRI study in 52 healthy volunteers, and it deliberately kept the compounds apart: one group received Semax, one received Selank, one received placebo^[5]. Nobody in that study received both. That gap is worth sitting with, because Selank has, separately, been tested in genuine combination protocols. A 2015 trial added Selank to the benzodiazepine phenazepam in 70 patients and reported the combined group reached benefit faster, with fewer of the benzodiazepine's side effects such as attention and memory impairment and sedation^[6]. Combination-arm studies of Selank exist. The specific pairing of Selank and Semax is not one of them. For someone trying peptides for the first time, taking two unstudied-together compounds at once removes the one advantage a first attempt has: if something changes, there is no way to know which peptide caused it.

What the evidence-based GAD pathway looks like, for comparison

It is worth knowing what the reviewed alternative looks like before adding an unauthorized import to the plan. The U.S. National Institute of Mental Health lists cognitive behavioral therapy as the most research-supported psychotherapy for GAD, and names SSRIs and SNRIs as the antidepressant classes most commonly prescribed, alongside short-term options such as benzodiazepines^[7]. None of that requires importing an unregulated peptide, and all of it comes with a clinician who can adjust the plan if something is not working, which is the feedback loop that stacking two untested peptides removes.

Neither peptide is an approved medicine outside Russia

Selank and Semax both sit on Russia's list of registered prescription medicines, but a search of the EU Clinical Trials Register returns zero registered trials for selank^[8] and zero for semax^[9]. Neither has a marketing authorization from the FDA, the EMA, or the MHRA, which means every vial sold outside Russia moves through the unregulated research-chemical market rather than a pharmacy with batch testing and adverse-event reporting behind it, the same supply reality that applies to grey-market peptides like BPC-157 and ipamorelin. Our Semax page walks through that regulatory picture in full, and the U.S. regulatory rundown for Semax covers what unapproved status means for import and possession specifically.

None of this is a verdict on whether Selank or Semax could ever help a given person. It is a description of what the published record does and does not contain: Selank has a small GAD trial behind it, Semax's focus reputation does not, and the combination of the two has never been studied in one person. Our separate look at Semax and Selank timing covers the same evidence gap from a dosing-schedule angle, and reaches the same conclusion: there is no schedule to report because none has been studied. If you are weighing this decision, a clinician who can review your history and the interaction risk against anything else you take is the right first call, not a forum thread. This article is educational and journalistic and is not medical advice.